A ‘Lobby’ Where a Molecule Mob Tells Genes What to Do
By Philip Ball,
Quanta Magazine
| 02. 14. 2024
The discovery during the Human Genome Project in the early 2000s that we humans have only about 20,000 protein-coding genes — about as many as the tiny soil-dwelling nematode worm, and less than half as many as the rice plant — came as a shock. That blow to our pride was softened, though, by the idea that the human genome is rich in regulatory connections. Our genes interact in a dense network, in which pieces of DNA and the molecules they encode (RNA and proteins) control the “expression” of other genes, influencing whether they make their respective RNA and proteins. To understand the human genome, we needed to understand this process of gene regulation.
That task, however, is proving to be much harder than decoding the sequence of the genome.
Initially, it was suspected that gene regulation was a simple matter of one gene product acting as an on/off switch for another gene, in digital fashion. In the 1960s, the French biologists François Jacob and Jacques Monod first elucidated a gene regulatory process in mechanistic detail: In Escherichia coli bacteria...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...